Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Larotrectinib Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Rhabdomyosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ewing Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Hepatoblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Kidney Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Malignant Germ Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Neuroblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Rhabdoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Skin Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Soft Tissue Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Cervical Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Lenalidomide Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Lenalidomide Myelodysplastic Syndrome With Excess Blasts-1	National Cancer Institute (NCI)	P2	CCC (53)
Lenalidomide Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	National Cancer Institute (NCI)	P2	CCC (53)

Showing 1626 to 1650 of 3,272 assets

PreviousPage 66 of 131Next